Get the Stockscreener App
8.72
4.60%
-0.42
After Hours:
8.65
-0.07
-0.80%
Regenxbio Inc stock is traded at $8.72, with a volume of 1.47M.
It is down -4.60% in the last 24 hours and down -15.01% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$9.14
Open:
$8.41
24h Volume:
1.47M
Relative Volume:
1.66
Market Cap:
$441.43M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.6578
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-0.34%
1M Performance:
-15.01%
6M Performance:
-10.20%
1Y Performance:
+39.52%
1-Day Range:
$8.01
$8.75
1-Week Range:
$8.01
$9.65
52-Week Range:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.72 | 462.70M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Morgan Stanley cuts Regenxbio stock price target on model updates - Investing.com
Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - marketscreener.com
Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Regenxbio Inc earnings missed by $0.58, revenue fell short of estimates - Investing.com UK
Earnings call transcript: Regenxbio misses Q4 2025 expectations, stock dips - Investing.com India
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Regenxbio: Q4 Earnings Snapshot - KVUE
REGENXBIO ($RGNX) Releases Q4 2025 Earnings - Quiver Quantitative
Regenxbio Q4 revenue rises but loss widens as costs increase - TradingView
Regenxbio Earnings Report: Q4 Overview - Benzinga
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Yahoo Finance
REGENXBIO (RGNX) Projected to Post Earnings on Thursday - MarketBeat
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
A Look Ahead: Regenxbio's Earnings Forecast - Benzinga
UPCOMING DEADLINE: REGENXBIO (RGNX) Securities Fraud Class Action – April 14, 2026 Lead Plaintiff Deadline - Seeking Alpha
REGENXBIO Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRGNX - Finviz
REGENXBIO to present new RGX-202 clinical data at 2026 MDA Clinical and Scientific Conference - Traders Union
REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - The AI Journal
New gene therapy data for Duchenne muscular dystrophy heads to MDA - Stock Titan
2026-03-04 | RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RGNX | Press Release - Stockhouse
REGENXBIO Inc. (NASDAQ:RGNX) Sees Significant Increase in Short Interest - MarketBeat
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Shareholders that lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class ActionRGNX - marketscreener.com
GSA Capital Partners LLP Has $100,000 Stock Holdings in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Stockholders Urged to Recover Losses - National Today
REGENXBIO, Inc. Stockholders Have RightsStockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses - Barchart.com
When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock - TipRanks
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Biotech REGENXBIO schedules three March investor talks, with webcast access - Stock Titan
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
REGENXBIO Inc. $RGNX Shares Purchased by JPMorgan Chase & Co. - MarketBeat
REGENXBIO Inc. (RGNX): Investor Outlook With A Promising 225% Upside Potential - DirectorsTalk Interviews
RegenXBio’s RGX-121 Hunter Syndrome Trial Faces Suspension: What Investors Should Know - TipRanks
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
Federal Circuit Revives REGENXBIO Gene Therapy Patent Suit Against Sarepta - Lawyer Monthly
Regenxbio Shares Face Significant Setback Following FDA Decision - AD HOC NEWS
Responsive Playbooks and the RGNX Inflection - Stock Traders Daily
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against REGENXBIO Inc. (RGNX)April 14, 2026 Deadline to Join – Contact The Gross Law Firm - marketscreener.com
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
RGNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regenxbio (RGNX) Likely to Surpass Earnings Predictions: Will the Share Price Rise? - Bitget
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Simpson Curran | Chief Executive Officer |
Oct 09 '25 |
Sale |
12.62 |
20,811 |
262,635 |
216,162 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):